Detailed description page of SalivaDB

This page displays user query in tabular form.

SAL_17629 details
Primary information
SALIDSAL_17629
Biomarker nameLithium [HMDB0005949]
Biomarker TypeNA
Sampling MethodAdult (>18 years old); Gender-female
Collection MethodNA
Analysis MethodNA
Collection SiteSaliva
Disease CategoryMental Disorder
Disease/ConditionMental disorder
Disease SubtypeNA
Fold Change/ Concentration760 +/- 230 uM
Up/DownregulatedNA
ExosomalNA
OrganismHomo sapiens
PMID22161502
Year of Publication2012
Biomarker ID3028194
Biomarker CategoryMetabolite
Sequence[Li]
Title of studyRelationship between serum lithium, salivary lithium, and urinary lithium in patients on lithium therapy
Abstract of studyLithium carbonate is used in the treatment of both psychiatric and nonpsychiatric disorders. The aim of this study was to explore the relationship between serum lithium, salivary lithium, and urinary lithium. Blood, saliva, and urine samples were collected from 50 patients, and estimation of serum, salivary, and urine lithium was done using an atomic absorption spectrophotometer. Mean serum lithium was 0.75 ± 0.25 mEq/L, mean salivary lithium was 1.91 ± 0.80 mEq/L, and mean urine lithium was 7.16 ± 4.84 mEq/L. A significant direct correlation was found between serum lithium and salivary lithium (r = 0.695, p < 0.001). This correlation was higher in females (r = 0.770, p < 0.001) when compared to males (r = 0.665, p < 0.001). Even though a significant correlation was found between serum and salivary lithium levels, more studies are needed in this domain to establish salivary therapeutic monitoring as a feasible option for patients on lithium carbonate therapy.